American Diabetes Association and IBM Watson Health Announce Long-Term Collaboration
Jun 12 16
The American Diabetes Association and IBM Watson Health announced a long-term collaboration to bring together the cognitive computing power of Watson and the Association's vast repository of clinical and research data. The organizations aim to build a diabetes advisor for patients and caregivers. The goal of the collaboration is to develop Watson-powered solutions that enable the diabetes community to optimize clinical, research and lifestyle decisions, and address important issues that influence health outcomes, such as social determinants of health. As part of the collaboration, Watson will be trained to understand diabetes data with the goal to identify potential risk factors and create evidence-based, confidence-ranked recommendations for a range of health decisions. Watson will ingest the Association's rich repository of clinical and scientific data, which includes 66 years of data, as well as the Association's aggregated data about self-management, support groups, health/wellness activities and diabetes education. New offerings developed through the collaboration may also draw on data and insights from IBM's Watson Health Cloud and will leverage Watson's capabilities, such as deep Q&A, natural language processing, engagement advisor, similarity analytics, predictive analytics and personality insights. For providers, the team plans to create a cognitive diabetes database to help inform treatment decisions and care management approaches. Healthcare providers could tap into personality insights through Watson to tailor their treatment approaches to the needs of an individual. Additionally, providers could identify and address potential risk factors for their patients by comparing an individual to population-level trends of patients with similar characteristics. For researchers, the Association and IBM Watson Health plan to create a cloud-based data and insights service that enables scientists to apply Watson to the Association's body of clinical and scientific evidence to help them find hidden patterns, potentially identifying the next frontiers for therapeutic discovery. This tool could accelerate significant breakthroughs in some of the most pressing areas of diabetes research. For patients and caregivers, cognitive tools for people living with diabetes or pre-diabetes could be developed to provide tailored information and insights, reflecting individual factors such as demographics, disease stage, treatment regimen and behaviors. For example, the collaboration could lead to the creation of a mobile app that is integrated with Watson Care Manager and may become increasingly personalized as individuals engage with it, effectively getting "smarter" each time it is used.
American Diabetes Association Announces New National Officers and Board Members
Jan 12 16
The American Diabetes Association announced its officers and Board of Directors members for 2016. The 2016 Board of Directors includes: Robin Richardson, Portland, Ore. (Chair of the Board) Richardson is Senior Vice President of Moda Health, where he is the senior executive responsible for the company's Integrated Health Systems, Pharmacy, Legislative, Medicare, and Medicaid programs as well as its Human Resources and Facilities departments. Margaret (Maggie) Powers, PhD, RD, CDE, Minneapolis (President, Health Care & Education) Powers conducts research and has a clinical practice as a registered dietitian and diabetes educator at the International Diabetes Center at Park Nicollet in Minneapolis. Desmond Schatz, MD, Gainesville, Fla. (President, Medicine & Science) Schatz is the Medical Director of the Diabetes Center, Professor and Associate Chairman of Pediatrics and Director of the Clinic Research Center at the University of Florida. Lorrie Welker Liang, Sarasota, Fla. (Secretary/Treasurer) Liang is Chief Operating Officer of Sarasota Memorial Health Care System. Prior to this appointment she served as Vice President of Sinai Hospital of Baltimore, a member of the Lifebridge Health System. Jackie Boucher, MS, RD, LD, CDE, Minneapolis Boucher is President of Children's HeartLink in Minneapolis. In this position she leads an organization focused on training doctors and nurses in underserved parts of the world to diagnose and treat children with heart disease, ensuring they receive quality care. Martha Clark, MBA, Lafayette, Ca. Clark is a retired senior-level executive with experience spanning the strategy consulting, asset management and banking industries. Most recently, she was part of the senior leadership team that grew a model-driven global equity investor for large institutions and then managed it through the financial crisis. David A. DeMarco, PhD, Wakefield, R.I. (Chair of the Board-Elect) DeMarco is a principal at Ernst & Young (EY) with more than 25 years of experience in strategy, innovation and management consulting. He currently serves as the Northeast Region Life Sciences Market Segment leader, where he oversees the full range of audit, tax, transaction and advisory services for the firm's pharmaceutical, biotech and medtech practice within the region. Robert H. Eckel, MD, Aurora, Colo. David Herrick, MBA, New York Herrick is President, U.S., Cohn & Wolfe. Felicia Hill-Briggs, PhD, ABPP, Baltimore Hill-Briggs is Professor of Medicine, Division of General Internal Medicine, Director, Behavior and Cognition Sub-Core, Healthcare and Population Science, Baltimore Diabetes Research Center, and Senior Director, Population Health Research and Development, The Johns Hopkins University School of Medicine, Welch Center for Prevention, Epidemiology, and Clinical Research. Jeffrey Himmel, MS, Miami Beach, Fla. Himmel is Chairman and Chief Executive Officer of The Himmel Group, Himmel Pharmaceuticals and Himmel Media where he markets consumer health care brands, over-the-counter pharmaceuticals, and health and nutrition products. Brenda Montgomery, RN, MSHS, CDE, Bellevue, Wash. (President-Elect, Health Care & Education) Montgomery is a Clinical Science Liaison for AstraZeneca Pharmaceuticals where she works with primary care providers to help with the treatment of diabetes and to ensure that they are up-to-date on standards of care, research and science. Alvin C. Powers, MD, Nashville, Tenn., (President-Elect, Medicine & Science) Powers is the Joe C. Davis Chair in Biologic Science and Professor of Medicine, Molecular Physiology and Biophysics at Vanderbilt University. He is also the Director of the Vanderbilt Diabetes Center, Chief of the Vanderbilt Division of Diabetes, Endocrinology and Metabolism, and the Director of the Vanderbilt Diabetes Research and Training Center. Jane Reusch, MD, Denver. Reusch is a Professor of Medicine, Biochemistry and Bioengineering and the Associate Director of the Center for Women's Health Research at the University of Colorado School of Medicine at the Anshultz Medical Campus. She is also the Director of the VA Diabetes Team at the Denver VA Medical Center. Calvin Schmidt, MBA, Raritan, N.J. Schmidt is President, Cardiovascular & Metabolism, Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, where he leads the growth of a business that is making a significant difference for patients suffering from cardiovascular and metabolic diseases. Catherine Squires, CFRE, Chicago Squires is President and CEO, NIU Foundation and Vice President for University Advancement at Northern Illinois University. Umesh Verma, Houston (Secretary/Treasurer-Elect) Verma is the Chief Executive Officer of BLUE LANCE, Inc. Alan L. Yatvin, JD, Philadelphia Yatvin is Managing Partner of the Philadelphia firm of Popper & Yatvin.